Availability of hepatitis C diagnostics and therapeutics in
European and Eurasia countries

J 2018

Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries

LEBLEBICIOGLU, Hakan; Joop E. ARENDS; Resat OZARAS; Giampaolo CORTI; Lurdes SANTOS et al.

Základní údaje

Originální název

Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries

Autoři

Vydání

ANTIVIRAL RESEARCH, AMSTERDAM, ELSEVIER SCIENCE BV, 2018, 0166-3542

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30303 Infectious Diseases

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 4.130

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/18:00102717

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Availability of hepatitis C diagnostics; Therapeutics in European and Eurasia countries

Štítky

14110214, EL OK, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 9. 2. 2019 21:03, Soňa Böhmová

Anotace

V originále

Background. Treatment with direct acting antiviral agents (DAAs) has provided sustained virological response rates in > 95% of patients with chronic hepatitis C virus (HCV) infection. However treatment is costly and market access, reimbursement and governmental restrictions differ among countries. We aimed to analyze these differences among European and Eurasian countries. Methods: A survey including 20-item questionnaire was sent to experts in viral hepatitis. Countries were evaluated according to their income categories by the World Bank stratification. Results: Experts from 26 countries responded to the survey. As of May 2016, HCV prevalence was reported as low (<= 1%) in Croatia, Czech Republic, Denmark, France, Germany, Hungary, the Netherlands, Portugal, Slovenia, Spain, Sweden, UK; intermediate (1-4%) in Azerbaijan, Bosnia and Herzegovina, Italy, Kosovo, Greece, Kazakhstan, Romania, Russia, Serbia and high in Georgia (6.7%). All countries had national guidelines except Albania, Kosovo, Serbia, Tunisia, and UK. Transient elastography was available in all countries, but reimbursed in 61%. HCV-RNA was reimbursed in 81%. PegIFN/RBV was reimbursed in 54% of the countries. No DAAs were available in four countries: Kazakhstan, Kosovo, Serbia, and Tunisia. In others, at least one DAA combination with either PegIFN/RBV or another DAA was available. In Germany and the Netherlands all DAAs were reimbursed without restrictions: Sofosbuvir and sofosbuvir/ledipasvir were free of charge in Georgia. Conclusion: Prevalence of HCV is relatively higher in lower-middle and upper-middle income countries. DAAs are not available or reimbursed in many Eurasia and European countries. Effective screening and access to care are essential for reducing liver-related morbidity and mortality.

Citovat

LEBLEBICIOGLU, Hakan; Joop E. ARENDS; Resat OZARAS; Giampaolo CORTI; Lurdes SANTOS; Christoph BOESECKE; Andrew USTIANOWSKI; Ann Sofi DUBERG; Simona RUTA; Nermin N. SALKIC; Petr HUSA; Ivana LAZAREVIC; Juan A. PINEDE; Natalia Y. PSHENICHNAYA; Tengiz TSERTSWADZE; Mojca MATICIC; Edmond PUCA; Gulzhan ABUOVA; Judit GERVAIN; Ramin BAYRAMLI; Salih AHMETI; Mairi KOULENTAKI; Badreddine KILANI; Adriana VINCE; Francesco NEGRO; Mustafa SUNBUL a Domonique SALMON. Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries. ANTIVIRAL RESEARCH. AMSTERDAM: ELSEVIER SCIENCE BV, 2018, roč. 150, FEB 2018, s. 9-14. ISSN 0166-3542. Dostupné z: https://doi.org/10.1016/j.antiviral.2017.12.001.

@article{1417176,
   author = {Leblebicioglu, Hakan and Arends, Joop E. and Ozaras, Resat and Corti, Giampaolo and Santos, Lurdes and Boesecke, Christoph and Ustianowski, Andrew and Duberg, Ann Sofi and Ruta, Simona and Salkic, Nermin N. and Husa, Petr and Lazarevic, Ivana and Pinede, Juan A. and Pshenichnaya, Natalia Y. and Tsertswadze, Tengiz and Maticic, Mojca and Puca, Edmond and Abuova, Gulzhan and Gervain, Judit and Bayramli, Ramin and Ahmeti, Salih and Koulentaki, Mairi and Kilani, Badreddine and Vince, Adriana and Negro, Francesco and Sunbul, Mustafa and Salmon, Domonique},
   article_location = {AMSTERDAM},
   article_number = {FEB 2018},
   doi = {https://doi.org/10.1016/j.antiviral.2017.12.001},
   keywords = {Availability of hepatitis C diagnostics; Therapeutics in European and Eurasia countries},
   language = {eng},
   issn = {0166-3542},
   journal = {ANTIVIRAL RESEARCH},
   title = {Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries},
   volume = {150},
   year = {2018}
}

TY  - JOUR
ID  - 1417176
AU  - Leblebicioglu, Hakan - Arends, Joop E. - Ozaras, Resat - Corti, Giampaolo - Santos, Lurdes - Boesecke, Christoph - Ustianowski, Andrew - Duberg, Ann Sofi - Ruta, Simona - Salkic, Nermin N. - Husa, Petr - Lazarevic, Ivana - Pinede, Juan A. - Pshenichnaya, Natalia Y. - Tsertswadze, Tengiz - Maticic, Mojca - Puca, Edmond - Abuova, Gulzhan - Gervain, Judit - Bayramli, Ramin - Ahmeti, Salih - Koulentaki, Mairi - Kilani, Badreddine - Vince, Adriana - Negro, Francesco - Sunbul, Mustafa - Salmon, Domonique
PY  - 2018
TI  - Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries
JF  - ANTIVIRAL RESEARCH
VL  - 150
IS  - FEB 2018
SP  - 9-14
EP  - 9-14
PB  - ELSEVIER SCIENCE BV
SN  - 01663542
KW  - Availability of hepatitis C diagnostics
KW  - Therapeutics in European and Eurasia countries
N2  - Background. Treatment with direct acting antiviral agents (DAAs) has provided sustained virological response rates in > 95% of patients with chronic hepatitis C virus (HCV) infection. However treatment is costly and market access, reimbursement and governmental restrictions differ among countries. We aimed to analyze these differences among European and Eurasian countries. Methods: A survey including 20-item questionnaire was sent to experts in viral hepatitis. Countries were evaluated according to their income categories by the World Bank stratification. Results: Experts from 26 countries responded to the survey. As of May 2016, HCV prevalence was reported as low (<= 1%) in Croatia, Czech Republic, Denmark, France, Germany, Hungary, the Netherlands, Portugal, Slovenia, Spain, Sweden, UK; intermediate (1-4%) in Azerbaijan, Bosnia and Herzegovina, Italy, Kosovo, Greece, Kazakhstan, Romania, Russia, Serbia and high in Georgia (6.7%). All countries had national guidelines except Albania, Kosovo, Serbia, Tunisia, and UK. Transient elastography was available in all countries, but reimbursed in 61%. HCV-RNA was reimbursed in 81%. PegIFN/RBV was reimbursed in 54% of the countries. No DAAs were available in four countries: Kazakhstan, Kosovo, Serbia, and Tunisia. In others, at least one DAA combination with either PegIFN/RBV or another DAA was available. In Germany and the Netherlands all DAAs were reimbursed without restrictions: Sofosbuvir and sofosbuvir/ledipasvir were free of charge in Georgia. Conclusion: Prevalence of HCV is relatively higher in lower-middle and upper-middle income countries. DAAs are not available or reimbursed in many Eurasia and European countries. Effective screening and access to care are essential for reducing liver-related morbidity and mortality.
ER  -

LEBLEBICIOGLU, Hakan; Joop E. ARENDS; Resat OZARAS; Giampaolo CORTI; Lurdes SANTOS; Christoph BOESECKE; Andrew USTIANOWSKI; Ann Sofi DUBERG; Simona RUTA; Nermin N. SALKIC; Petr HUSA; Ivana LAZAREVIC; Juan A. PINEDE; Natalia Y. PSHENICHNAYA; Tengiz TSERTSWADZE; Mojca MATICIC; Edmond PUCA; Gulzhan ABUOVA; Judit GERVAIN; Ramin BAYRAMLI; Salih AHMETI; Mairi KOULENTAKI; Badreddine KILANI; Adriana VINCE; Francesco NEGRO; Mustafa SUNBUL a Domonique SALMON. Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries. \textit{ANTIVIRAL RESEARCH}. AMSTERDAM: ELSEVIER SCIENCE BV, 2018, roč.~150, FEB 2018, s.~9-14. ISSN~0166-3542. Dostupné z: https://doi.org/10.1016/j.antiviral.2017.12.001.

Přehled o publikaci